Are CB2 Receptors a New Target for Schizophrenia Treatment?

Schizophrenia is a complex disorder that involves several neurotransmitters such as dopamine, glutamate, and GABA. More recently, the endocannabinoid system has also been associated with this disorder. Although initially described as present mostly in the periphery, cannabinoid type-2 (CB2) receptor...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in psychiatry Vol. 11; p. 587154
Main Authors Cortez, Isadora L, Rodrigues da Silva, Naielly, Guimarães, Francisco S, Gomes, Felipe V
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 30.10.2020
Subjects
cannabinoids
dopamine
endocannabinoid system
microglia
Psychiatry
psychosis
cannabinoids
endocannabinoid system
dopamine
microglia
psychosis
Online AccessGet full text

Cover

Abstract Schizophrenia is a complex disorder that involves several neurotransmitters such as dopamine, glutamate, and GABA. More recently, the endocannabinoid system has also been associated with this disorder. Although initially described as present mostly in the periphery, cannabinoid type-2 (CB2) receptors are now proposed to play a role in several brain processes related to schizophrenia, such as modulation of dopaminergic neurotransmission, microglial activation, and neuroplastic changes induced by stress. Here, we reviewed studies describing the involvement of the CB2 receptor in these processes and their association with the pathophysiology of schizophrenia. Taken together, these pieces of evidence indicate that CB2 receptor may emerge as a new target for the development of antipsychotic drugs.
AbstractList Schizophrenia is a complex disorder that involves several neurotransmitters such as dopamine, glutamate, and GABA. More recently, the endocannabinoid system has also been associated with this disorder. Although initially described as present mostly in the periphery, cannabinoid type-2 (CB2) receptors are now proposed to play a role in several brain processes related to schizophrenia, such as modulation of dopaminergic neurotransmission, microglial activation, and neuroplastic changes induced by stress. Here, we reviewed studies describing the involvement of the CB2 receptor in these processes and their association with the pathophysiology of schizophrenia. Taken together, these pieces of evidence indicate that CB2 receptor may emerge as a new target for the development of antipsychotic drugs.
Author Guimarães, Francisco S
Gomes, Felipe V
Cortez, Isadora L
Rodrigues da Silva, Naielly
AuthorAffiliation Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo , Ribeirão Preto , Brazil
AuthorAffiliation_xml – name: Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo , Ribeirão Preto , Brazil
Author_xml – sequence: 1
  givenname: Isadora L
  surname: Cortez
  fullname: Cortez, Isadora L
  organization: Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
– sequence: 2
  givenname: Naielly
  surname: Rodrigues da Silva
  fullname: Rodrigues da Silva, Naielly
  organization: Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
– sequence: 3
  givenname: Francisco S
  surname: Guimarães
  fullname: Guimarães, Francisco S
  organization: Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
– sequence: 4
  givenname: Felipe V
  surname: Gomes
  fullname: Gomes, Felipe V
  organization: Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33329132$$D View this record in MEDLINE/PubMed
BookMark eNpVkUtvGyEQgFGVKA83P6CXao-92AVmFxZVapVYeViKEqnxHbEw2Butly2sE6W_viROo4QLDMx8M-g7Jnt96JGQL4zOAGr13Q_paZxxyumsqiWryk_kiAlRTqko6d678yE5Seme5gVKgagOyCEAcMWAH5EfpxGL-RkvfqPFYQwxFaa4wcdiaeIKx8KHWNzZdfs3DOuIfWuKZUQzbrAff30m-950CU9e9wlZXpwv51fT69vLxfz0empLUY1T4VUNDfWMUykMMO5FxepaVU4yx_LgpWmAOS7QG9FYB6p2RlrpMIdewIQsdlgXzL0eYrsx8UkH0-qXixBX2sSxtR1q6huROSC9p6WkqCSvlAQGqqxF6Wxm_dyxhm2zQWfzN6LpPkA_vvTtWq_Cg5ZCAijIgG-vgBj-bDGNetMmi11negzbpHluqygIqnIq26XaGFKK6N_aMKqfFeoXhfpZod4pzDVf38_3VvFfGPwDzKKYkg
CitedBy_id crossref_primary_10_1016_j_neubiorev_2024_105699
crossref_primary_10_1080_15622975_2022_2038797
crossref_primary_10_1089_can_2021_0127
crossref_primary_10_1111_bph_16383
crossref_primary_10_1007_s12035_022_02800_y
crossref_primary_10_1007_s00406_024_01788_x
crossref_primary_10_1177_20451253221128445
crossref_primary_10_30773_pi_2022_0343
crossref_primary_10_3390_ijms23094764
crossref_primary_10_31466_kfbd_1214649
crossref_primary_10_1016_j_mce_2021_111522
crossref_primary_10_1016_j_phrs_2021_105729
crossref_primary_10_1016_j_phrs_2021_105938
crossref_primary_10_3390_ijms22158168
crossref_primary_10_1007_s00406_021_01334_z
crossref_primary_10_1016_j_euroneuro_2023_01_005
crossref_primary_10_3390_cimb45040228
crossref_primary_10_1007_s00213_021_05905_9
Cites_doi 10.1126/science.1148045
10.1007/3-540-26573-2_10
10.1177/0004867415589793
10.1097/00001756-199906030-00008
10.1016/j.bbi.2015.06.002
10.1007/s12640-017-9702-4
10.1016/S0149-7634(05)80152-6
10.1007/s00213-009-1612-6
10.1038/s41419-019-2174-0
10.1016/j.chembiol.2007.11.006
10.3389/fnins.2017.00030
10.3390/molecules23081836
10.1016/j.nbd.2019.104625
10.1002/glia.20838
10.1523/JNEUROSCI.4540-04.2005
10.1038/nrdp.2015.67
10.1001/archpsyc.64.6.633
10.1016/j.pnpbp.2006.08.013
10.1074/jbc.M707960200
10.1001/archpsyc.64.8.978-a
10.1007/s00018-016-2300-4
10.1001/archpsyc.1994.03950030035004
10.1016/j.mehy.2013.03.013
10.1016/S0165-5728(96)00196-8
10.1016/j.schres.2011.03.022
10.1016/j.schres.2004.09.007
10.1111/bph.12478
10.1016/j.neubiorev.2008.03.012
10.1016/j.biopsych.2008.04.025
10.1192/bjp.bp.108.053843
10.1111/j.1476-5381.2010.00729.x
10.1007/978-3-7091-6844-8_18
10.1016/j.euroneuro.2008.04.002
10.3390/ph3082517
10.1523/JNEUROSCI.23-04-01398.2003
10.1016/j.schres.2015.01.015
10.1111/bph.13139
10.1093/ijnp/pyw102
10.2174/13894501113149990208
10.1017/S1462399409000957
10.1098/rstb.2011.0389
10.1016/j.bbr.2010.10.008
10.1523/JNEUROSCI.3695-04.2004
10.2174/157015907780866884
10.1016/j.nbd.2019.104646
10.1038/s41598-017-17796-y
10.1016/S0920-9964(01)00296-1
10.1124/mol.111.071290
10.1111/adb.12367
10.1016/j.bbi.2009.09.012
10.3390/molecules191117078
10.1016/j.biopsych.2020.03.016
10.1016/j.biopsych.2009.09.024
10.1038/npp.2013.165
10.1196/annals.1432.036
10.1586/ern.11.89
10.1007/s12035-016-9697-5
10.1016/S0140-6736(95)91325-4
10.1038/sj.mp.4002066
10.1007/s00213-019-05370-5
10.1016/S1567-5769(01)00147-3
10.1146/annurev-psych-113011-143739
10.1016/j.ebiom.2019.03.040
10.1016/j.plipres.2009.07.001
10.3389/fnins.2014.00361
10.1016/S0140-6736(07)61721-8
10.2967/jnumed.109.066647
10.1016/j.mce.2008.01.001
10.1038/tp.2017.4
10.1111/j.1460-9568.1998.00292.x
10.1038/aps.2016.149
10.1016/j.euroneuro.2007.05.005
10.1097/ACO.0000000000000616
10.1038/sj.mp.4001748
10.1007/978-4-431-53945-2_6
10.1038/sj.mp.4001029
10.1017/S1092852914000601
10.1186/1742-2094-2-29
10.1016/j.phrs.2020.104749
10.1124/pr.110.003491
10.1016/S0140-6736(13)60733-3
10.1385/CRIAI:28:3:249
10.1046/j.1532-5415.2002.50619.x
10.1016/j.bbr.2015.01.051
10.1016/j.drugalcdep.2009.07.002
10.1016/j.brainres.2005.11.035
10.1146/annurev-physiol-022516-034406
10.1523/JNEUROSCI.3400-08.2008
10.1017/S1461145710000313
10.1016/j.neuron.2004.05.019
10.1074/jbc.M111.291294
10.1038/sj.bjp.0707505
10.1038/tp.2012.56
10.1016/S0920-9964(98)00034-6
10.1016/j.schres.2019.01.030
10.1097/YPG.0000000000000047
10.1016/j.bcp.2018.09.013
10.1038/npp.2011.43
10.1016/S2215-0366(18)30345-6
10.1016/S2215-0366(14)70307-4
10.1016/j.neuron.2016.08.017
10.1007/s00213-014-3481-x
10.1038/tp.2017.120
10.1038/sj.bjp.0707442
10.1093/ijnp/pyu041
10.1016/j.bbi.2017.10.021
10.4088/JCP.08m04666yel
10.1016/j.mvr.2009.03.005
10.1038/emm.2015.100
10.1016/j.pbb.2008.05.010
10.1016/j.schres.2006.11.016
10.1016/j.bbi.2006.02.002
10.1038/mp.2009.52
10.1038/365061a0
10.1111/j.1471-4159.2005.03380.x
10.1186/1476-511X-2-5
10.1007/s00702-019-02080-2
10.1161/STROKEAHA.111.631044
10.1001/archpsyc.62.9.985
10.1016/j.neubiorev.2020.04.020
10.1016/j.pnpbp.2011.12.002
10.1017/neu.2016.69
10.1038/mp.2017.47
10.1016/j.bbr.2015.12.034
10.1007/s12640-016-9662-0
10.1007/s00406-004-0548-4
10.1016/j.schres.2017.01.050
10.1093/brain/awp239
10.1038/npp.2012.22
10.1126/science.1115740
10.1001/jamapsychiatry.2019.2508
10.3389/neuro.08.014.2009
10.1016/j.pnpbp.2007.08.031
10.1101/cshperspect.a019026
10.1016/j.biopsych.2015.07.028
10.1038/27919
10.1177/0269881111400652
10.1111/j.1476-5381.2010.00819.x
10.1016/S2215-0366(14)00122-9
10.1002/syn.22061
10.3389/fneur.2016.00005
10.1017/S1461145710000209
10.1016/j.neuropharm.2018.03.001
10.1016/j.pnpbp.2018.04.004
10.1124/pr.54.2.161
10.2174/138161212802884681
10.1056/NEJMoa051688
10.1016/j.stemcr.2014.01.009
10.1016/j.bbr.2018.11.043
10.1016/j.biopsych.2016.07.014
10.1038/npp.2013.101
10.1111/j.1460-9568.2007.05322.x
10.1001/jamapsychiatry.2019.0844
10.1093/schbul/sbx199
10.1016/j.biopsych.2015.11.007
10.1038/sj.npp.1300558
10.1124/mol.65.4.999
10.1016/j.pain.2009.02.018
10.1111/pcn.12823
10.1038/npp.2011.34
10.1073/pnas.1413210111
10.1093/schbul/sbs010
10.1038/nm.4218
10.2147/TCRM.S117321
10.1038/nn.2874
10.1016/B978-0-12-802206-1.00017-9
10.1038/384083a0
10.1016/j.neuropharm.2019.107740
10.1016/j.tips.2006.11.001
10.1017/S1092852918001013
10.1016/j.pnpbp.2015.03.017
10.1038/s41593-018-0334-7
ContentType Journal Article
Copyright Copyright © 2020 Cortez, Rodrigues da Silva, Guimarães and Gomes.
Copyright © 2020 Cortez, Rodrigues da Silva, Guimarães and Gomes. 2020 Cortez, Rodrigues da Silva, Guimarães and Gomes
Copyright_xml – notice: Copyright © 2020 Cortez, Rodrigues da Silva, Guimarães and Gomes.
– notice: Copyright © 2020 Cortez, Rodrigues da Silva, Guimarães and Gomes. 2020 Cortez, Rodrigues da Silva, Guimarães and Gomes
DBID NPM
AAYXX
CITATION
7X8
5PM
DOA
DOI 10.3389/fpsyt.2020.587154
DatabaseName PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList

PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
EISSN 1664-0640
EndPage 587154
ExternalDocumentID oai_doaj_org_article_0fb626e37ff0470e97259731394864dc
10_3389_fpsyt_2020_587154
33329132
Genre Journal Article
Review
GrantInformation_xml – fundername: Conselho Nacional de Desenvolvimento Científico e Tecnológico
  grantid: 465458/2014-9
– fundername: Fundação de Amparo à Pesquisa do Estado de São Paulo
  grantid: 2017/24304-0; 2018/17597-3
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
ABIVO
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
DIK
EMOBN
GROUPED_DOAJ
GX1
HYE
IAO
IEA
IHR
IHW
IPNFZ
IPY
KQ8
M48
M~E
NPM
O5R
O5S
OK1
PGMZT
RIG
RNS
RPM
AAYXX
CITATION
7X8
5PM
AFPKN
ID FETCH-LOGICAL-c465t-6f983b0f12076a312f6518895d71d11544ab31d26efa6bcd398da7c7dea6bf63
IEDL.DBID RPM
ISSN 1664-0640
IngestDate Tue Oct 22 15:14:31 EDT 2024
Tue Sep 17 21:08:00 EDT 2024
Fri Oct 25 01:30:22 EDT 2024
Thu Nov 21 22:34:58 EST 2024
Sat Oct 05 05:29:49 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords cannabinoids
endocannabinoid system
dopamine
microglia
psychosis
Language English
License Copyright © 2020 Cortez, Rodrigues da Silva, Guimarães and Gomes.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c465t-6f983b0f12076a312f6518895d71d11544ab31d26efa6bcd398da7c7dea6bf63
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Reviewed by: Daniel Umbricht, Roche, Switzerland; Jorge Manzanares, Miguel Hernández University of Elche, Spain
Edited by: Sagnik Bhattacharyya, King's College London, United Kingdom
This article was submitted to Psychopharmacology, a section of the journal Frontiers in Psychiatry
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673393/
PMID 33329132
PQID 2470903609
PQPubID 23479
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_0fb626e37ff0470e97259731394864dc
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7673393
proquest_miscellaneous_2470903609
crossref_primary_10_3389_fpsyt_2020_587154
pubmed_primary_33329132
PublicationCentury 2000
PublicationDate 2020-10-30
PublicationDateYYYYMMDD 2020-10-30
PublicationDate_xml – month: 10
  year: 2020
  text: 2020-10-30
  day: 30
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in psychiatry
PublicationTitleAlternate Front Psychiatry
PublicationYear 2020
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Atwood (B48) 2010; 160
Pruessner (B159) 2011; 129
Renard (B27) 2014; 8
Glausier (B13) 2017; 181
Diana (B81) 1998; 10
Chung (B147) 2016; 48
Sickle (B50) 2005; 310
Licinio (B116) 1997; 49
Yu (B166) 2014; 2
Christensen (B85) 2007; 370
Galaj (B109) 2020; 167
Van Kesteren (B127) 2017; 7
Aracil-Fernández (B89) 2012; 37
Miyaoka (B131) 2007; 31
Onaivi (B53) 2012; 26
Howes (B5) 2017; 81
Mecha (B142) 2015; 49
Lin (B121) 1998; 32
Bilbo (B125) 2009; 3
Bubeníková-Valešová (B97) 2008; 32
Turcotte (B45) 2016; 73
Murray (B4) 2008; 18
De Marchi (B40) 2003; 2
Ashton (B43) 2007; 5
Zuardi (B41) 2011; 11
Deakin (B135) 2018; 5
Grace (B73) 2019; 45
Canseco-Alba (B78) 2019; 360
Leweke (B39) 1999; 10
Miller (B55) 2011; 63
Racz (B51) 2008; 28
Yun (B161) 2016; 22
Silins (B29) 2014; 1
Bie (B46) 2018; 31
Zarruk (B145) 2012; 43
Beckstead (B77) 2004; 42
Krystal (B96) 2005; 62
Lu (B17) 2016; 79
Walton (B164) 2012; 2
Zuardi (B106) 2012; 18
Zhang (B122) 2002; 57
Bland (B126) 2010; 24
Lisboa (B57) 2016; 7
Zhang (B91) 2017; 22
Steullet (B101) 2017; 22
Carrier (B59) 2004; 65
Fiorillo (B75) 1998; 394
Onaivi (B52) 2008; 1139
Cassano (B63) 2017; 11
Akhondzadeh (B137) 2007; 90
Zhang (B90) 2014; 111
Leucht (B173) 2013; 382
Müller (B136) 2005; 255
Avraham (B169) 2014; 171
Khella (B104) 2014; 231
Bioque (B38) 2013; 38
Zhang (B144) 2009; 78
Ortega-Alvaro (B66) 2011; 36
Cabral (B44) 2009; 11
Ishiguro (B67) 2018; 23
Rodrigues da Silva (B110) 2020; 156
Taga (B113) 2005; 28
Takano (B130) 2010; 13
Gómez-Gálvez (B152) 2016; 64
Lieberman (B7) 2005; 353
Blankman (B22) 2007; 14
Söderlund (B123) 2009; 14
Lopes (B88) 2020; 237
Ramírez (B148) 2005; 25
Hong (B167) 2019; 10
Carlisle (B138) 2002; 2
Manzanares (B80) 2018; 157
Palazuelos (B143) 2008; 283
Palazuelos (B171) 2012; 287
Carbon (B3) 2014; 19
Ishiguro (B71) 2010; 67
Volk (B16) 2019; 76
Kruk-Slomka (B34) 2016; 30
Ashdown (B124) 2006; 11
SvíŽenská (B47) 2008; 90
Rentsch (B150) 2020; 134
Perkins (B120) 2020; 88
Koethe (B37) 2009; 194
Hamdani (B32) 2008; 18
Wolf (B118) 2017; 79
Gomes (B111) 2015; 164
Doorduin (B129) 2009; 50
Molina-Holgado (B170) 2007; 25
Mackie (B24) 2005; 168
Wilson (B115) 2002; 50
Andreasen (B2) 1995; 346
Ward (B83) 2009; 105
Kruk-Slomka (B105) 2017; 31
Palazuelos (B154) 2009; 132
van Berckel (B128) 2008; 64
Martín-Moreno (B149) 2011; 79
Flores (B162) 2016; 301
Du (B160) 2013; 38
García-Gutiérrez (B68) 2010; 160
Xi (B79) 2011; 14
Petitto (B114) 1997; 73
Giuffrida (B36) 2004; 29
Ma (B93) 2019; 42
Walter (B58) 2003; 23
Filip (B86) 2003; 55
Solmi (B8) 2017; 13
Uno (B15) 2019; 73
Gomes (B157) 2019; 213
Behrens (B103) 2007; 318
Chen (B20) 2017; 38
Levkovitz (B133) 2010; 71
Ehrhart (B60) 2005; 2
Nasrallah (B6) 2008; 13
Mintz (B11) 2007; 64
Pertwee (B26) 2008; 153
Walker (B158) 2013; 14
Guidali (B33) 2011; 14
Khandaker (B69) 2015; 2
Riegel (B82) 2004; 24
Liu (B92) 2017; 7
Bae (B31) 2014; 24
Eggers (B12) 2013; 80
Roche (B65) 2010; 3
Fernandez-Espejo (B28) 2009; 206
Fogaça (B108) 2018; 135
Howlett (B23) 2002; 54
Benito (B56) 2008; 153
Fernández-Ruiz (B61) 2008; 286
Foster (B94) 2016; 91
Braun (B151) 2018; 68
Legge (B72) 2019; 76
Leonard (B70) 2018; 30
Osumi (B168) 2011
Drzyzga (B112) 2006; 20
Fakhoury (B25) 2017; 54
Sánchez-Zavaleta (B54) 2018; 72
Paladini (B76) 2016; 24
Grace (B74) 2017; 81
Hu (B155) 2009; 143
Kahn (B1) 2015; 1
Delis (B87) 2017; 20
Yu (B84) 2011; 217
Kaar (B100) 2019; 126
Fujita (B132) 2008; 32
Dalton (B35) 2011; 36
Morais (B172) 2017; 7
Munro (B42) 1993; 365
Stahl (B14) 2018; 23
Monji (B146) 2013; 42
Maresz (B139) 2005; 95
Maccarrone (B18) 2009; 48
Fernández-Ruiz (B140) 2007; 28
Zhang (B134) 2018; 85
Keefe (B10) 2007; 64
Sagredo (B153) 2009; 57
Fezza (B19) 2014; 19
Ujike (B30) 2002; 7
Banaszkiewicz (B64) 2020; 114
Gonzalez-Burgos (B98) 2012; 38
Mechoulam (B62) 2013; 64
Gomes (B102) 2015; 18
Campos (B107) 2012; 367
Kruk-Slomka (B156) 2015; 284
Rothwell (B117) 1993; 17
Gong (B49) 2006; 1071
Allen (B165) 2016; 50
Orihuela (B141) 2016; 173
Krystal (B95) 1994; 51
Nuechterlein (B9) 2004; 72
Sellgren (B119) 2019; 22
Kang (B163) 2016; 8
Cravatt (B21) 1996; 384
Hudson (B99) 2020; 134
References_xml – volume: 318
  start-page: 1645
  year: 2007
  ident: B103
  article-title: Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase
  publication-title: Science.
  doi: 10.1126/science.1148045
  contributor:
    fullname: Behrens
– volume: 168
  start-page: 299
  year: 2005
  ident: B24
  article-title: Distribution of cannabinoid receptors in the central and peripheral nervous system
  publication-title: Handb Exp Pharmacol.
  doi: 10.1007/3-540-26573-2_10
  contributor:
    fullname: Mackie
– volume: 50
  start-page: 473
  year: 2016
  ident: B165
  article-title: Cell proliferation is reduced in the hippocampus in schizophrenia
  publication-title: Aust N Z J Psychiatry.
  doi: 10.1177/0004867415589793
  contributor:
    fullname: Allen
– volume: 10
  start-page: 1665
  year: 1999
  ident: B39
  article-title: Elevated endogenous cannabinoids in schizophrenia
  publication-title: Neuroreport.
  doi: 10.1097/00001756-199906030-00008
  contributor:
    fullname: Leweke
– volume: 49
  start-page: 233
  year: 2015
  ident: B142
  article-title: Endocannabinoids drive the acquisition of an alternative phenotype in microglia
  publication-title: Brain Behav Immun.
  doi: 10.1016/j.bbi.2015.06.002
  contributor:
    fullname: Mecha
– volume: 31
  start-page: 410
  year: 2017
  ident: B105
  article-title: The impact of CB2 receptor ligands on the MK-801-induced hyperactivity in mice
  publication-title: Neurotox Res.
  doi: 10.1007/s12640-017-9702-4
  contributor:
    fullname: Kruk-Slomka
– volume: 17
  start-page: 217
  year: 1993
  ident: B117
  article-title: Involvement of cytokines in acute neurodegeneration in the CNS
  publication-title: Neurosci Biobehav Rev.
  doi: 10.1016/S0149-7634(05)80152-6
  contributor:
    fullname: Rothwell
– volume: 206
  start-page: 531
  year: 2009
  ident: B28
  article-title: Role of cannabis and endocannabinoids in the genesis of schizophrenia
  publication-title: Psychopharmacology (Berl).
  doi: 10.1007/s00213-009-1612-6
  contributor:
    fullname: Fernandez-Espejo
– volume: 10
  start-page: 943
  year: 2019
  ident: B167
  article-title: Defective neurogenesis and schizophrenia-like behavior in PARP-1-deficient mice
  publication-title: Cell Death Dis.
  doi: 10.1038/s41419-019-2174-0
  contributor:
    fullname: Hong
– volume: 14
  start-page: 1347
  year: 2007
  ident: B22
  article-title: A Comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol
  publication-title: Chem Biol.
  doi: 10.1016/j.chembiol.2007.11.006
  contributor:
    fullname: Blankman
– volume: 11
  start-page: 30
  year: 2017
  ident: B63
  article-title: Cannabinoid receptor 2 signaling in neurodegenerative disorders: from pathogenesis to a promising therapeutic target
  publication-title: Front Neurosci.
  doi: 10.3389/fnins.2017.00030
  contributor:
    fullname: Cassano
– volume: 23
  start-page: 1836
  year: 2018
  ident: B67
  article-title: Cannabinoid CB2 receptor gene and environmental interaction in the development of psychiatric disorders
  publication-title: Molecules.
  doi: 10.3390/molecules23081836
  contributor:
    fullname: Ishiguro
– volume: 134
  start-page: 104625
  year: 2020
  ident: B99
  article-title: NMDA receptors on parvalbumin-positive interneurons and pyramidal neurons both contribute to MK-801 induced gamma oscillatory disturbances: complex relationships with behaviour
  publication-title: Neurobiol Dis.
  doi: 10.1016/j.nbd.2019.104625
  contributor:
    fullname: Hudson
– volume: 57
  start-page: 1154
  year: 2009
  ident: B153
  article-title: Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease
  publication-title: Glia.
  doi: 10.1002/glia.20838
  contributor:
    fullname: Sagredo
– volume: 25
  start-page: 1904
  year: 2005
  ident: B148
  article-title: Prevention of Alzheimer's disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation
  publication-title: J Neurosci.
  doi: 10.1523/JNEUROSCI.4540-04.2005
  contributor:
    fullname: Ramírez
– volume: 1
  start-page: 15067
  year: 2015
  ident: B1
  article-title: Schizophrenia
  publication-title: Nat Rev Dis Prim.
  doi: 10.1038/nrdp.2015.67
  contributor:
    fullname: Kahn
– volume: 64
  start-page: 633
  year: 2007
  ident: B10
  article-title: Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial
  publication-title: Arch Gen Psychiatry.
  doi: 10.1001/archpsyc.64.6.633
  contributor:
    fullname: Keefe
– volume: 31
  start-page: 304
  year: 2007
  ident: B131
  article-title: Possible antipsychotic effects of minocycline in patients with schizophrenia
  publication-title: Prog Neuropsychopharmacol Biol Psychiatry.
  doi: 10.1016/j.pnpbp.2006.08.013
  contributor:
    fullname: Miyaoka
– volume: 283
  start-page: 13320
  year: 2008
  ident: B143
  article-title: The CB2 cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis
  publication-title: J Biol Chem.
  doi: 10.1074/jbc.M707960200
  contributor:
    fullname: Palazuelos
– volume: 64
  start-page: 978
  year: 2007
  ident: B11
  article-title: CUtLASS confirms CATIE [2]
  publication-title: Arch Gen Psychiatry.
  doi: 10.1001/archpsyc.64.8.978-a
  contributor:
    fullname: Mintz
– volume: 73
  start-page: 4449
  year: 2016
  ident: B45
  article-title: The CB2 receptor and its role as a regulator of inflammation
  publication-title: Cell Mol Life Sci.
  doi: 10.1007/s00018-016-2300-4
  contributor:
    fullname: Turcotte
– volume: 51
  start-page: 199
  year: 1994
  ident: B95
  article-title: Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans
  publication-title: Arch Gen Psychiatry.
  doi: 10.1001/archpsyc.1994.03950030035004
  contributor:
    fullname: Krystal
– volume: 80
  start-page: 791
  year: 2013
  ident: B12
  article-title: A serotonin hypothesis of schizophrenia
  publication-title: Med Hypotheses.
  doi: 10.1016/j.mehy.2013.03.013
  contributor:
    fullname: Eggers
– volume: 73
  start-page: 183
  year: 1997
  ident: B114
  article-title: Modulation of behavioral and neurochemical measures of forebrain dopamine function in mice by species-specific interleukin-2
  publication-title: J Neuroimmunol.
  doi: 10.1016/S0165-5728(96)00196-8
  contributor:
    fullname: Petitto
– volume: 129
  start-page: 29
  year: 2011
  ident: B159
  article-title: Stress and protective factors in individuals at ultra-high risk for psychosis, first episode psychosis and healthy controls
  publication-title: Schizophr Res.
  doi: 10.1016/j.schres.2011.03.022
  contributor:
    fullname: Pruessner
– volume: 72
  start-page: 29
  year: 2004
  ident: B9
  article-title: Identification of separable cognitive factors in schizophrenia
  publication-title: Schizophr Res.
  doi: 10.1016/j.schres.2004.09.007
  contributor:
    fullname: Nuechterlein
– volume: 171
  start-page: 468
  year: 2014
  ident: B169
  article-title: The cannabinoid CB2 receptor agonist AM1241 enhances neurogenesis in GFAP/Gp120 transgenic mice displaying deficits in neurogenesis
  publication-title: Br J Pharmacol.
  doi: 10.1111/bph.12478
  contributor:
    fullname: Avraham
– volume: 32
  start-page: 1014
  year: 2008
  ident: B97
  article-title: Models of schizophrenia in humans and animals based on inhibition of NMDA receptors
  publication-title: Neurosci Biobehav Rev.
  doi: 10.1016/j.neubiorev.2008.03.012
  contributor:
    fullname: Bubeníková-Valešová
– volume: 64
  start-page: 820
  year: 2008
  ident: B128
  article-title: Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study
  publication-title: Biol Psychiatry.
  doi: 10.1016/j.biopsych.2008.04.025
  contributor:
    fullname: van Berckel
– volume: 194
  start-page: 371
  year: 2009
  ident: B37
  article-title: Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis
  publication-title: Br J Psychiatry.
  doi: 10.1192/bjp.bp.108.053843
  contributor:
    fullname: Koethe
– volume: 160
  start-page: 467
  year: 2010
  ident: B48
  article-title: CB 2: a cannabinoid receptor with an identity crisis
  publication-title: Br J Pharmacol.
  doi: 10.1111/j.1476-5381.2010.00729.x
  contributor:
    fullname: Atwood
– volume: 49
  start-page: 169
  year: 1997
  ident: B116
  article-title: Central nervous system cytokines and their relevance for neurotoxicity and apoptosis
  publication-title: J Neural Transm Suppl.
  doi: 10.1007/978-3-7091-6844-8_18
  contributor:
    fullname: Licinio
– volume: 18
  start-page: S129
  year: 2008
  ident: B4
  article-title: Schizophrenia: from developmental deviance to dopamine dysregulation
  publication-title: Eur Neuropsychopharmacol.
  doi: 10.1016/j.euroneuro.2008.04.002
  contributor:
    fullname: Murray
– volume: 3
  start-page: 2517
  year: 2010
  ident: B65
  article-title: Brain CB2 receptors: implications for neuropsychiatric disorders
  publication-title: Pharmaceuticals.
  doi: 10.3390/ph3082517
  contributor:
    fullname: Roche
– volume: 23
  start-page: 1398
  year: 2003
  ident: B58
  article-title: Nonpsychotropic cannabinoid receptors regulate microglial cell migration
  publication-title: J Neurosci.
  doi: 10.1523/JNEUROSCI.23-04-01398.2003
  contributor:
    fullname: Walter
– volume: 164
  start-page: 155
  year: 2015
  ident: B111
  article-title: Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol
  publication-title: Schizophr Res.
  doi: 10.1016/j.schres.2015.01.015
  contributor:
    fullname: Gomes
– volume: 173
  start-page: 649
  year: 2016
  ident: B141
  article-title: Microglial M1/M2 polarization and metabolic states
  publication-title: Br J Pharmacol.
  doi: 10.1111/bph.13139
  contributor:
    fullname: Orihuela
– volume: 20
  start-page: 269
  year: 2017
  ident: B87
  article-title: Attenuation of cocaine-induced conditioned place preference and motor activity via cannabinoid CB2 receptor agonism and cb1 receptor antagonism in rats
  publication-title: Int J Neuropsychopharmacol.
  doi: 10.1093/ijnp/pyw102
  contributor:
    fullname: Delis
– volume: 14
  start-page: 1262
  year: 2013
  ident: B158
  article-title: Acute and chronic stress-induced disturbances of microglial plasticity, phenotype and function
  publication-title: Curr Drug Targets.
  doi: 10.2174/13894501113149990208
  contributor:
    fullname: Walker
– volume: 11
  start-page: e3
  year: 2009
  ident: B44
  article-title: Emerging role of the CB2 cannabinoid receptor in immune regulation and therapeutic prospects
  publication-title: Expert Rev Mol Med.
  doi: 10.1017/S1462399409000957
  contributor:
    fullname: Cabral
– volume: 367
  start-page: 3364
  year: 2012
  ident: B107
  article-title: Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders
  publication-title: Philos Trans R Soc B Biol Sci.
  doi: 10.1098/rstb.2011.0389
  contributor:
    fullname: Campos
– volume: 217
  start-page: 111
  year: 2011
  ident: B84
  article-title: Effects of cannabinoid CB1 receptor antagonist rimonabant on acquisition and reinstatement of psychostimulant reward memory in mice
  publication-title: Behav Brain Res.
  doi: 10.1016/j.bbr.2010.10.008
  contributor:
    fullname: Yu
– volume: 24
  start-page: 11070
  year: 2004
  ident: B82
  article-title: Independent presynaptic and postsynaptic mechanisms regulate endocannabinoid signaling at multiple synapses in the ventral tegmental area
  publication-title: J Neurosci.
  doi: 10.1523/JNEUROSCI.3695-04.2004
  contributor:
    fullname: Riegel
– volume: 5
  start-page: 73
  year: 2007
  ident: B43
  article-title: The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration
  publication-title: Curr Neuropharmacol.
  doi: 10.2174/157015907780866884
  contributor:
    fullname: Ashton
– volume: 134
  start-page: 104646
  year: 2020
  ident: B150
  article-title: Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia
  publication-title: Neurobiol Dis.
  doi: 10.1016/j.nbd.2019.104646
  contributor:
    fullname: Rentsch
– volume: 7
  start-page: 17410
  year: 2017
  ident: B92
  article-title: Cannabinoid type 2 receptors in dopamine neurons inhibits psychomotor behaviors, alters anxiety, depression and alcohol preference
  publication-title: Sci Rep.
  doi: 10.1038/s41598-017-17796-y
  contributor:
    fullname: Liu
– volume: 57
  start-page: 247
  year: 2002
  ident: B122
  article-title: Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia : Association with psychopathology
  publication-title: Schizophr Res.
  doi: 10.1016/S0920-9964(01)00296-1
  contributor:
    fullname: Zhang
– volume: 79
  start-page: 964
  year: 2011
  ident: B149
  article-title: Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease
  publication-title: Mol Pharmacol.
  doi: 10.1124/mol.111.071290
  contributor:
    fullname: Martín-Moreno
– volume: 22
  start-page: 752
  year: 2017
  ident: B91
  article-title: Expression of functional cannabinoid CB2 receptor in VTA dopamine neurons in rats
  publication-title: Addict Biol.
  doi: 10.1111/adb.12367
  contributor:
    fullname: Zhang
– volume: 24
  start-page: 329
  year: 2010
  ident: B126
  article-title: Enduring consequences of early-life infection on glial and neural cell genesis within cognitive regions of the brain
  publication-title: Brain Behav Immun.
  doi: 10.1016/j.bbi.2009.09.012
  contributor:
    fullname: Bland
– volume: 19
  start-page: 17078
  year: 2014
  ident: B19
  article-title: Endocannabinoids, related compounds and their metabolic routes
  publication-title: Molecules.
  doi: 10.3390/molecules191117078
  contributor:
    fullname: Fezza
– volume: 88
  start-page: 326
  year: 2020
  ident: B120
  article-title: Potential roles of redox dysregulation in the development of schizophrenia
  publication-title: Biol Psychiatry.
  doi: 10.1016/j.biopsych.2020.03.016
  contributor:
    fullname: Perkins
– volume: 67
  start-page: 974
  year: 2010
  ident: B71
  article-title: Brain cannabinoid CB2 receptor in schizophrenia
  publication-title: Biol Psychiatry.
  doi: 10.1016/j.biopsych.2009.09.024
  contributor:
    fullname: Ishiguro
– volume: 38
  start-page: 2568
  year: 2013
  ident: B38
  article-title: Peripheral endocannabinoid system dysregulation in first-episode psychosis
  publication-title: Neuropsychopharmacology.
  doi: 10.1038/npp.2013.165
  contributor:
    fullname: Bioque
– volume: 1139
  start-page: 43449
  year: 2008
  ident: B52
  article-title: Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression
  publication-title: Ann N Y Acad Sci.
  doi: 10.1196/annals.1432.036
  contributor:
    fullname: Onaivi
– volume: 11
  start-page: 1111
  year: 2011
  ident: B41
  article-title: Is the highest density of CB1 receptors in paranoid schizophrenia a correlate of endocannabinoid system functioning?
  publication-title: Expert Rev Neurother.
  doi: 10.1586/ern.11.89
  contributor:
    fullname: Zuardi
– volume: 54
  start-page: 768
  year: 2017
  ident: B25
  article-title: Role of the Endocannabinoid system in the pathophysiology of schizophrenia
  publication-title: Mol Neurobiol.
  doi: 10.1007/s12035-016-9697-5
  contributor:
    fullname: Fakhoury
– volume: 346
  start-page: 477
  year: 1995
  ident: B2
  article-title: Symptoms, signs, and diagnosis of schizophrenia
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(95)91325-4
  contributor:
    fullname: Andreasen
– volume: 13
  start-page: 27
  year: 2008
  ident: B6
  article-title: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles
  publication-title: Mol Psychiatry.
  doi: 10.1038/sj.mp.4002066
  contributor:
    fullname: Nasrallah
– volume: 237
  start-page: 385
  year: 2020
  ident: B88
  article-title: The roles of cannabinoid CB1 and CB2 receptors in cocaine-induced behavioral sensitization and conditioned place preference in mice
  publication-title: Psychopharmacology (Berl).
  doi: 10.1007/s00213-019-05370-5
  contributor:
    fullname: Lopes
– volume: 2
  start-page: 69
  year: 2002
  ident: B138
  article-title: Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation
  publication-title: Int Immunopharmacol.
  doi: 10.1016/S1567-5769(01)00147-3
  contributor:
    fullname: Carlisle
– volume: 64
  start-page: 21
  year: 2013
  ident: B62
  article-title: The endocannabinoid system and the brain
  publication-title: Annu Rev Psychol.
  doi: 10.1146/annurev-psych-113011-143739
  contributor:
    fullname: Mechoulam
– volume: 42
  start-page: 225
  year: 2019
  ident: B93
  article-title: Mechanisms of cannabinoid CB 2 receptor-mediated reduction of dopamine neuronal excitability in mouse ventral tegmental area
  publication-title: EBioMedicine.
  doi: 10.1016/j.ebiom.2019.03.040
  contributor:
    fullname: Ma
– volume: 48
  start-page: 344
  year: 2009
  ident: B18
  article-title: Endocannabinoids: friends and foes of reproduction
  publication-title: Prog Lipid Res.
  doi: 10.1016/j.plipres.2009.07.001
  contributor:
    fullname: Maccarrone
– volume: 8
  start-page: 361
  year: 2014
  ident: B27
  article-title: Long-term consequences of adolescent cannabinoid exposure in adult psychopathology
  publication-title: Front Neurosci.
  doi: 10.3389/fnins.2014.00361
  contributor:
    fullname: Renard
– volume: 370
  start-page: 1706
  year: 2007
  ident: B85
  article-title: Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(07)61721-8
  contributor:
    fullname: Christensen
– volume: 50
  start-page: 1801
  year: 2009
  ident: B129
  article-title: Neuroinflammation in schizophrenia-related psychosis: a PET study
  publication-title: J Nucl Med.
  doi: 10.2967/jnumed.109.066647
  contributor:
    fullname: Doorduin
– volume: 286
  start-page: S91
  year: 2008
  ident: B61
  article-title: Role of CB2 receptors in neuroprotective effects of cannabinoids
  publication-title: Mol Cell Endocrinol.
  doi: 10.1016/j.mce.2008.01.001
  contributor:
    fullname: Fernández-Ruiz
– volume: 7
  start-page: e1075
  year: 2017
  ident: B127
  article-title: Immune involvement in the pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies
  publication-title: Transl Psychiatry.
  doi: 10.1038/tp.2017.4
  contributor:
    fullname: Van Kesteren
– volume: 10
  start-page: 2825
  year: 1998
  ident: B81
  article-title: Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids
  publication-title: Eur J Neurosci.
  doi: 10.1111/j.1460-9568.1998.00292.x
  contributor:
    fullname: Diana
– volume: 38
  start-page: 312
  year: 2017
  ident: B20
  article-title: Brain cannabinoid receptor 2: expression, function and modulation
  publication-title: Acta Pharmacol Sin.
  doi: 10.1038/aps.2016.149
  contributor:
    fullname: Chen
– volume: 18
  start-page: 34
  year: 2008
  ident: B32
  article-title: The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia
  publication-title: Eur Neuropsychopharmacol.
  doi: 10.1016/j.euroneuro.2007.05.005
  contributor:
    fullname: Hamdani
– volume: 31
  start-page: 407
  year: 2018
  ident: B46
  article-title: An overview of the cannabinoid type 2 receptor system and its therapeutic potential
  publication-title: Curr Opin Anaesthesiol.
  doi: 10.1097/ACO.0000000000000616
  contributor:
    fullname: Bie
– volume: 11
  start-page: 47
  year: 2006
  ident: B124
  article-title: The role of cytokines in mediating effects of prenatal infection on the fetus: Implications for schizophrenia
  publication-title: Mol Psychiatry.
  doi: 10.1038/sj.mp.4001748
  contributor:
    fullname: Ashdown
– start-page: 111
  year: 2011
  ident: B168
  article-title: Impaired neurogenesis as a risk factor for schizophrenia and related mental diseases
  publication-title: Neurogenesis in the Adult Brain II
  doi: 10.1007/978-4-431-53945-2_6
  contributor:
    fullname: Osumi
– volume: 7
  start-page: 515
  year: 2002
  ident: B30
  article-title: CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia
  publication-title: Mol Psychiatry.
  doi: 10.1038/sj.mp.4001029
  contributor:
    fullname: Ujike
– volume: 19
  start-page: 38
  year: 2014
  ident: B3
  article-title: Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia
  publication-title: CNS Spectr.
  doi: 10.1017/S1092852914000601
  contributor:
    fullname: Carbon
– volume: 2
  start-page: 29
  year: 2005
  ident: B60
  article-title: Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation
  publication-title: J Neuroinflammation.
  doi: 10.1186/1742-2094-2-29
  contributor:
    fullname: Ehrhart
– volume: 156
  start-page: 104749
  year: 2020
  ident: B110
  article-title: Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors
  publication-title: Pharmacol Res.
  doi: 10.1016/j.phrs.2020.104749
  contributor:
    fullname: Rodrigues da Silva
– volume: 63
  start-page: 461
  year: 2011
  ident: B55
  article-title: The highs and lows of cannabinoid receptor expression in disease: Mechanisms and their therapeutic implications
  publication-title: Pharmacol Rev.
  doi: 10.1124/pr.110.003491
  contributor:
    fullname: Miller
– volume: 382
  start-page: 951
  year: 2013
  ident: B173
  article-title: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(13)60733-3
  contributor:
    fullname: Leucht
– volume: 28
  start-page: 249
  year: 2005
  ident: B113
  article-title: Role of IL-6 in the neural stem cell differentiation
  publication-title: Clin Rev Allergy Immunol.
  doi: 10.1385/CRIAI:28:3:249
  contributor:
    fullname: Taga
– volume: 50
  start-page: 2041
  year: 2002
  ident: B115
  article-title: Cytokines and cognition - the case for a head-to-toe inflammatory paradigm
  publication-title: J Am Geriatr Soc.
  doi: 10.1046/j.1532-5415.2002.50619.x
  contributor:
    fullname: Wilson
– volume: 284
  start-page: 24
  year: 2015
  ident: B156
  article-title: Antidepressant-like effects of the cannabinoid receptor ligands in the forced swimming test in mice: mechanism of action and possible interactions with cholinergic system
  publication-title: Behav Brain Res.
  doi: 10.1016/j.bbr.2015.01.051
  contributor:
    fullname: Kruk-Slomka
– volume: 105
  start-page: 248
  year: 2009
  ident: B83
  article-title: The CB1 antagonist rimonabant (SR141716) blocks cue-induced reinstatement of cocaine seeking and other context and extinction phenomena predictive of relapse
  publication-title: Drug Alcohol Depend.
  doi: 10.1016/j.drugalcdep.2009.07.002
  contributor:
    fullname: Ward
– volume: 1071
  start-page: 10
  year: 2006
  ident: B49
  article-title: Cannabinoid CB2 receptors: immunohistochemical localization in rat brain
  publication-title: Brain Res.
  doi: 10.1016/j.brainres.2005.11.035
  contributor:
    fullname: Gong
– volume: 79
  start-page: 619
  year: 2017
  ident: B118
  article-title: Microglia in physiology and disease
  publication-title: Annu Rev Physiol.
  doi: 10.1146/annurev-physiol-022516-034406
  contributor:
    fullname: Wolf
– volume: 28
  start-page: 12125
  year: 2008
  ident: B51
  article-title: Crucial role of CB2 cannabinoid receptor in the regulation of central immune responses during neuropathic pain
  publication-title: J Neurosci.
  doi: 10.1523/JNEUROSCI.3400-08.2008
  contributor:
    fullname: Racz
– volume: 13
  start-page: 943
  year: 2010
  ident: B130
  article-title: Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106
  publication-title: Int J Neuropsychopharmacol.
  doi: 10.1017/S1461145710000313
  contributor:
    fullname: Takano
– volume: 42
  start-page: 939
  year: 2004
  ident: B77
  article-title: Vesicular dopamine release elicits an inhibitory postsynaptic current in midbrain dopamine neurons
  publication-title: Neuron.
  doi: 10.1016/j.neuron.2004.05.019
  contributor:
    fullname: Beckstead
– volume: 287
  start-page: 1198
  year: 2012
  ident: B171
  article-title: CB2 cannabinoid receptors promote neural progenitor cell proliferation via mTORC1 signaling
  publication-title: J Biol Chem.
  doi: 10.1074/jbc.M111.291294
  contributor:
    fullname: Palazuelos
– volume: 153
  start-page: 277
  year: 2008
  ident: B56
  article-title: Cannabinoid CB2 receptors in human brain inflammation
  publication-title: Br J Pharmacol.
  doi: 10.1038/sj.bjp.0707505
  contributor:
    fullname: Benito
– volume: 2
  start-page: e135
  year: 2012
  ident: B164
  article-title: Detection of an immature dentate gyrus feature in human schizophrenia/bipolar patients
  publication-title: Transl Psychiatry.
  doi: 10.1038/tp.2012.56
  contributor:
    fullname: Walton
– volume: 32
  start-page: 9
  year: 1998
  ident: B121
  article-title: The inflammatory response system in treatment-resistant schizophrenia: Increased serum interleukin-6
  publication-title: Schizophr Res.
  doi: 10.1016/S0920-9964(98)00034-6
  contributor:
    fullname: Lin
– volume: 213
  start-page: 107
  year: 2019
  ident: B157
  article-title: Stress during critical periods of development and risk for schizophrenia
  publication-title: Schizophr Res.
  doi: 10.1016/j.schres.2019.01.030
  contributor:
    fullname: Gomes
– volume: 24
  start-page: 225
  year: 2014
  ident: B31
  article-title: Genetic association analysis of CNR1 and CNR2 polymorphisms with schizophrenia in a Korean population
  publication-title: Psychiatr Genet.
  doi: 10.1097/YPG.0000000000000047
  contributor:
    fullname: Bae
– volume: 157
  start-page: 108
  year: 2018
  ident: B80
  article-title: Role of the endocannabinoid system in drug addiction
  publication-title: Biochem Pharmacol.
  doi: 10.1016/j.bcp.2018.09.013
  contributor:
    fullname: Manzanares
– volume: 36
  start-page: 1620
  year: 2011
  ident: B35
  article-title: Paranoid schizophrenia is characterized by increased CB 1 receptor binding in the dorsolateral prefrontal cortex
  publication-title: Neuropsychopharmacology.
  doi: 10.1038/npp.2011.43
  contributor:
    fullname: Dalton
– volume: 5
  start-page: 885
  year: 2018
  ident: B135
  article-title: The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial
  publication-title: Lancet Psychiatry.
  doi: 10.1016/S2215-0366(18)30345-6
  contributor:
    fullname: Deakin
– volume: 1
  start-page: 286
  year: 2014
  ident: B29
  article-title: Young adult sequelae of adolescent cannabis use: an integrative analysis
  publication-title: Lancet Psychiatry.
  doi: 10.1016/S2215-0366(14)70307-4
  contributor:
    fullname: Silins
– volume: 91
  start-page: 1244
  year: 2016
  ident: B94
  article-title: Antipsychotic-like effects of M4 positive allosteric modulators are mediated by CB2 receptor-dependent inhibition of dopamine release
  publication-title: Neuron.
  doi: 10.1016/j.neuron.2016.08.017
  contributor:
    fullname: Foster
– volume: 231
  start-page: 3071
  year: 2014
  ident: B104
  article-title: CB2 receptor agonism reverses MK-801-induced disruptions of prepulse inhibition in mice
  publication-title: Psychopharmacology (Berl).
  doi: 10.1007/s00213-014-3481-x
  contributor:
    fullname: Khella
– volume: 7
  start-page: e1146
  year: 2017
  ident: B172
  article-title: The modulation of adult neuroplasticity is involved in the mood-improving actions of atypical antipsychotics in an animal model of depression
  publication-title: Transl Psychiatry.
  doi: 10.1038/tp.2017.120
  contributor:
    fullname: Morais
– volume: 153
  start-page: 199
  year: 2008
  ident: B26
  article-title: The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids: Δ 9-tetrahydrocannabinol, cannabidiol and Δ 9-tetrahydrocannabivarin
  publication-title: Br J Pharmacol.
  doi: 10.1038/sj.bjp.0707442
  contributor:
    fullname: Pertwee
– volume: 18
  start-page: 1
  year: 2015
  ident: B102
  article-title: Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in Mice
  publication-title: Int J Neuropsychopharmacol.
  doi: 10.1093/ijnp/pyu041
  contributor:
    fullname: Gomes
– volume: 68
  start-page: 224
  year: 2018
  ident: B151
  article-title: Selective activation of cannabinoid receptor-2 reduces neuroinflammation after traumatic brain injury via alternative macrophage polarization
  publication-title: Brain Behav Immun.
  doi: 10.1016/j.bbi.2017.10.021
  contributor:
    fullname: Braun
– volume: 71
  start-page: 138
  year: 2010
  ident: B133
  article-title: A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia
  publication-title: J Clin Psychiatry.
  doi: 10.4088/JCP.08m04666yel
  contributor:
    fullname: Levkovitz
– volume: 78
  start-page: 86
  year: 2009
  ident: B144
  article-title: CB2 receptor activation attenuates microcirculatory dysfunction during cerebral ischemic/reperfusion injury
  publication-title: Microvasc Res.
  doi: 10.1016/j.mvr.2009.03.005
  contributor:
    fullname: Zhang
– volume: 48
  start-page: e205
  year: 2016
  ident: B147
  article-title: CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson's disease
  publication-title: Exp Mol Med.
  doi: 10.1038/emm.2015.100
  contributor:
    fullname: Chung
– volume: 90
  start-page: 501
  year: 2008
  ident: B47
  article-title: Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures - a short review
  publication-title: Pharmacol Biochem Behav.
  doi: 10.1016/j.pbb.2008.05.010
  contributor:
    fullname: SvíŽenská
– volume: 90
  start-page: 179
  year: 2007
  ident: B137
  article-title: Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial
  publication-title: Schizophr Res.
  doi: 10.1016/j.schres.2006.11.016
  contributor:
    fullname: Akhondzadeh
– volume: 20
  start-page: 532
  year: 2006
  ident: B112
  article-title: Cytokines in schizophrenia and the effects of antipsychotic drugs
  publication-title: Brain Behav Immun.
  doi: 10.1016/j.bbi.2006.02.002
  contributor:
    fullname: Drzyzga
– volume: 14
  start-page: 1069
  year: 2009
  ident: B123
  article-title: Activation of brain interleukin-1? in schizophrenia
  publication-title: Mol Psychiatry.
  doi: 10.1038/mp.2009.52
  contributor:
    fullname: Söderlund
– volume: 365
  start-page: 61
  year: 1993
  ident: B42
  article-title: Molecular characterization of a peripheral receptor for cannabinoids
  publication-title: Nature.
  doi: 10.1038/365061a0
  contributor:
    fullname: Munro
– volume: 95
  start-page: 437
  year: 2005
  ident: B139
  article-title: Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli
  publication-title: J Neurochem.
  doi: 10.1111/j.1471-4159.2005.03380.x
  contributor:
    fullname: Maresz
– volume: 2
  start-page: 5
  year: 2003
  ident: B40
  article-title: Endocannabinoid signalling in the blood of patients with schizophrenia
  publication-title: Lipids Health Dis.
  doi: 10.1186/1476-511X-2-5
  contributor:
    fullname: De Marchi
– volume: 126
  start-page: 1637
  year: 2019
  ident: B100
  article-title: Pre-frontal parvalbumin interneurons in schizophrenia: a meta-analysis of post-mortem studies
  publication-title: J Neural Transm (Vienna).
  doi: 10.1007/s00702-019-02080-2
  contributor:
    fullname: Kaar
– volume: 43
  start-page: 211
  year: 2012
  ident: B145
  article-title: Cannabinoid type 2 receptor activation downregulates stroke-induced classic and alternative brain macrophage/microglial activation concomitant to neuroprotection
  publication-title: Stroke.
  doi: 10.1161/STROKEAHA.111.631044
  contributor:
    fullname: Zarruk
– volume: 62
  start-page: 985
  year: 2005
  ident: B96
  article-title: Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function
  publication-title: Arch Gen Psychiatry.
  doi: 10.1001/archpsyc.62.9.985
  contributor:
    fullname: Krystal
– volume: 114
  start-page: 158
  year: 2020
  ident: B64
  article-title: Contribution of CB2 receptors in schizophrenia-related symptoms in various animal models: short review
  publication-title: Neurosci Biobehav Rev.
  doi: 10.1016/j.neubiorev.2020.04.020
  contributor:
    fullname: Banaszkiewicz
– volume: 55
  start-page: 1125
  year: 2003
  ident: B86
  article-title: Blocking impact of clozapine on cocaine locomotor and sensitizing effects in rats
  publication-title: Pol J Pharmacol.
  contributor:
    fullname: Filip
– volume: 42
  start-page: 115
  year: 2013
  ident: B146
  article-title: Neuroinflammation in schizophrenia especially focused on the role of microglia
  publication-title: Prog Neuropsychopharmacol Biol Psychiatry.
  doi: 10.1016/j.pnpbp.2011.12.002
  contributor:
    fullname: Monji
– volume: 30
  start-page: 1
  year: 2018
  ident: B70
  article-title: Inflammation and depression: a causal or coincidental link to the pathophysiology?
  publication-title: Acta Neuropsychiatr.
  doi: 10.1017/neu.2016.69
  contributor:
    fullname: Leonard
– volume: 22
  start-page: 936
  year: 2017
  ident: B101
  article-title: Oxidative stress-driven parvalbumin interneuron impairment as a common mechanism in models of schizophrenia
  publication-title: Mol Psychiatry.
  doi: 10.1038/mp.2017.47
  contributor:
    fullname: Steullet
– volume: 301
  start-page: 190
  year: 2016
  ident: B162
  article-title: Neuronal and brain morphological changes in animal models of schizophrenia
  publication-title: Behav Brain Res.
  doi: 10.1016/j.bbr.2015.12.034
  contributor:
    fullname: Flores
– volume: 30
  start-page: 658
  year: 2016
  ident: B34
  article-title: The Influence of the CB1 receptor ligands on the schizophrenia-like effects in mice induced by MK-801
  publication-title: Neurotox Res.
  doi: 10.1007/s12640-016-9662-0
  contributor:
    fullname: Kruk-Slomka
– volume: 255
  start-page: 149
  year: 2005
  ident: B136
  article-title: Clinical effects of COX-2 inhibitors on cognition in schizophrenia
  publication-title: Eur Arch Psychiatry Clin Neurosci.
  doi: 10.1007/s00406-004-0548-4
  contributor:
    fullname: Müller
– volume: 181
  start-page: 2
  year: 2017
  ident: B13
  article-title: GABA and schizophrenia: where we stand and where we need to go
  publication-title: Schizophr Res.
  doi: 10.1016/j.schres.2017.01.050
  contributor:
    fullname: Glausier
– volume: 132
  start-page: 3152
  year: 2009
  ident: B154
  article-title: Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity
  publication-title: Brain.
  doi: 10.1093/brain/awp239
  contributor:
    fullname: Palazuelos
– volume: 37
  start-page: 1749
  year: 2012
  ident: B89
  article-title: Decreased cocaine motor sensitization and self-administration in mice overexpressing cannabinoid CB2receptors
  publication-title: Neuropsychopharmacology.
  doi: 10.1038/npp.2012.22
  contributor:
    fullname: Aracil-Fernández
– volume: 310
  start-page: 329
  year: 2005
  ident: B50
  article-title: Identification and functional characterization of brainstem cannabinoid CB2 receptor
  publication-title: Science.
  doi: 10.1126/science.1115740
  contributor:
    fullname: Sickle
– volume: 76
  start-page: 1256
  year: 2019
  ident: B72
  article-title: Association of genetic liability to psychotic experiences with neuropsychotic disorders and traits
  publication-title: JAMA Psychiatry.
  doi: 10.1001/jamapsychiatry.2019.2508
  contributor:
    fullname: Legge
– volume: 3
  start-page: 14
  year: 2009
  ident: B125
  article-title: Early-life programming of later-life brain and behavior: a critical role for the immune system
  publication-title: Front Behav Neurosci.
  doi: 10.3389/neuro.08.014.2009
  contributor:
    fullname: Bilbo
– volume: 32
  start-page: 336
  year: 2008
  ident: B132
  article-title: Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline
  publication-title: Prog Neuropsychopharmacol Biol Psychiatry.
  doi: 10.1016/j.pnpbp.2007.08.031
  contributor:
    fullname: Fujita
– volume: 8
  start-page: a019026
  year: 2016
  ident: B163
  article-title: Adult neurogenesis and psychiatric disorders
  publication-title: Cold Spring Harb Perspect Biol.
  doi: 10.1101/cshperspect.a019026
  contributor:
    fullname: Kang
– volume: 79
  start-page: 516
  year: 2016
  ident: B17
  article-title: An introduction to the endogenous cannabinoid system
  publication-title: Biol Psychiatry.
  doi: 10.1016/j.biopsych.2015.07.028
  contributor:
    fullname: Lu
– volume: 394
  start-page: 78
  year: 1998
  ident: B75
  article-title: Glutamate mediates an inhibitory postsynaptic potential in dopamine neurons
  publication-title: Nature.
  doi: 10.1038/27919
  contributor:
    fullname: Fiorillo
– volume: 26
  start-page: 92
  year: 2012
  ident: B53
  article-title: CNS effects of CB2 cannabinoid receptors: Beyond neuro-immuno-cannabinoid activity
  publication-title: J Psychopharmacol.
  doi: 10.1177/0269881111400652
  contributor:
    fullname: Onaivi
– volume: 160
  start-page: 1773
  year: 2010
  ident: B68
  article-title: Depression-resistant endophenotype in mice overexpressing cannabinoid CB 2 receptors
  publication-title: Br J Pharmacol.
  doi: 10.1111/j.1476-5381.2010.00819.x
  contributor:
    fullname: García-Gutiérrez
– volume: 2
  start-page: 258
  year: 2015
  ident: B69
  article-title: Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment
  publication-title: Lancet Psychiatry.
  doi: 10.1016/S2215-0366(14)00122-9
  contributor:
    fullname: Khandaker
– volume: 72
  start-page: 52
  year: 2018
  ident: B54
  article-title: Presynaptic cannabinoid CB2 receptors modulate [3 H]-Glutamate release at subthalamo-nigral terminals of the rat
  publication-title: Synapse.
  doi: 10.1002/syn.22061
  contributor:
    fullname: Sánchez-Zavaleta
– volume: 7
  start-page: 5
  year: 2016
  ident: B57
  article-title: Microglial cells as a link between cannabinoids and the immune hypothesis of psychiatric disorders
  publication-title: Front Neurol.
  doi: 10.3389/fneur.2016.00005
  contributor:
    fullname: Lisboa
– volume: 14
  start-page: 17
  year: 2011
  ident: B33
  article-title: Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine
  publication-title: Int J Neuropsychopharmacol.
  doi: 10.1017/S1461145710000209
  contributor:
    fullname: Guidali
– volume: 135
  start-page: 22
  year: 2018
  ident: B108
  article-title: The anxiolytic effects of cannabidiol in chronically stressed mice are mediated by the endocannabinoid system: role of neurogenesis and dendritic remodeling
  publication-title: Neuropharmacology.
  doi: 10.1016/j.neuropharm.2018.03.001
  contributor:
    fullname: Fogaça
– volume: 85
  start-page: 69
  year: 2018
  ident: B134
  article-title: Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: Association with pro-inflammatory cytokine levels
  publication-title: Prog Neuropsychopharmacol Biol Psychiatry.
  doi: 10.1016/j.pnpbp.2018.04.004
  contributor:
    fullname: Zhang
– volume: 54
  start-page: 161
  year: 2002
  ident: B23
  article-title: International Union of Pharmacology. XXVII. Classification of cannabinoid receptors
  publication-title: Pharmacol Rev.
  doi: 10.1124/pr.54.2.161
  contributor:
    fullname: Howlett
– volume: 18
  start-page: 5131
  year: 2012
  ident: B106
  article-title: A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation
  publication-title: Curr Pharm Des.
  doi: 10.2174/138161212802884681
  contributor:
    fullname: Zuardi
– volume: 353
  start-page: 1209
  year: 2005
  ident: B7
  article-title: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMoa051688
  contributor:
    fullname: Lieberman
– volume: 2
  start-page: 295
  year: 2014
  ident: B166
  article-title: Modeling hippocampal neurogenesis using human pluripotent stem cells
  publication-title: Stem Cell Reports.
  doi: 10.1016/j.stemcr.2014.01.009
  contributor:
    fullname: Yu
– volume: 360
  start-page: 286
  year: 2019
  ident: B78
  article-title: Behavioral effects of psychostimulants in mutant mice with cell-type specific deletion of CB2 cannabinoid receptors in dopamine neurons
  publication-title: Behav Brain Res.
  doi: 10.1016/j.bbr.2018.11.043
  contributor:
    fullname: Canseco-Alba
– volume: 81
  start-page: 9
  year: 2017
  ident: B5
  article-title: The role of genes, stress, and dopamine in the development of schizophrenia
  publication-title: Biol Psychiatry.
  doi: 10.1016/j.biopsych.2016.07.014
  contributor:
    fullname: Howes
– volume: 38
  start-page: 1881
  year: 2013
  ident: B160
  article-title: Peripubertal diazepam administration prevents the emergence of dopamine system hyperresponsivity in the MAM developmental disruption model of schizophrenia
  publication-title: Neuropsychopharmacology.
  doi: 10.1038/npp.2013.101
  contributor:
    fullname: Du
– volume: 25
  start-page: 629
  year: 2007
  ident: B170
  article-title: CB2 cannabinoid receptors promote mouse neural stem cell proliferation
  publication-title: Eur J Neurosci.
  doi: 10.1111/j.1460-9568.2007.05322.x
  contributor:
    fullname: Molina-Holgado
– volume: 76
  start-page: 887
  year: 2019
  ident: B16
  article-title: Insights into the pathophysiology of endocannabinoid signaling in schizophrenia
  publication-title: JAMA Psychiatry.
  doi: 10.1001/jamapsychiatry.2019.0844
  contributor:
    fullname: Volk
– volume: 45
  start-page: 148
  year: 2019
  ident: B73
  article-title: The circuitry of dopamine system regulation and its disruption in schizophrenia: insights into treatment and prevention
  publication-title: Schizophr Bull.
  doi: 10.1093/schbul/sbx199
  contributor:
    fullname: Grace
– volume: 81
  start-page: 5
  year: 2017
  ident: B74
  article-title: Dopamine system dysregulation and the pathophysiology of schizophrenia: insights from the methylazoxymethanol acetate model
  publication-title: Biol Psychiatry.
  doi: 10.1016/j.biopsych.2015.11.007
  contributor:
    fullname: Grace
– volume: 29
  start-page: 2108
  year: 2004
  ident: B36
  article-title: Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms
  publication-title: Neuropsychopharmacology.
  doi: 10.1038/sj.npp.1300558
  contributor:
    fullname: Giuffrida
– volume: 65
  start-page: 999
  year: 2004
  ident: B59
  article-title: Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism
  publication-title: Mol Pharmacol.
  doi: 10.1124/mol.65.4.999
  contributor:
    fullname: Carrier
– volume: 143
  start-page: 206
  year: 2009
  ident: B155
  article-title: Depression-like behaviour in rats with mononeuropathy is reduced by the CB2-selective agonist GW405833
  publication-title: Pain.
  doi: 10.1016/j.pain.2009.02.018
  contributor:
    fullname: Hu
– volume: 73
  start-page: 204
  year: 2019
  ident: B15
  article-title: Glutamate hypothesis in schizophrenia
  publication-title: Psychiatry Clin Neurosci.
  doi: 10.1111/pcn.12823
  contributor:
    fullname: Uno
– volume: 36
  start-page: 1489
  year: 2011
  ident: B66
  article-title: Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice
  publication-title: Neuropsychopharmacology.
  doi: 10.1038/npp.2011.34
  contributor:
    fullname: Ortega-Alvaro
– volume: 111
  start-page: E5007
  year: 2014
  ident: B90
  article-title: Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice
  publication-title: Proc Natl Acad Sci U S A.
  doi: 10.1073/pnas.1413210111
  contributor:
    fullname: Zhang
– volume: 38
  start-page: 950
  year: 2012
  ident: B98
  article-title: NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia
  publication-title: Schizophr Bull.
  doi: 10.1093/schbul/sbs010
  contributor:
    fullname: Gonzalez-Burgos
– volume: 22
  start-page: 1239
  year: 2016
  ident: B161
  article-title: Re-evaluating the link between neuropsychiatric disorders and dysregulated adult neurogenesis
  publication-title: Nat Med.
  doi: 10.1038/nm.4218
  contributor:
    fullname: Yun
– volume: 13
  start-page: 757
  year: 2017
  ident: B8
  article-title: Safety, tolerability, and risks associated with first-and second-generation antipsychotics: a state-of-the-art clinical review
  publication-title: Ther Clin Risk Manag.
  doi: 10.2147/TCRM.S117321
  contributor:
    fullname: Solmi
– volume: 14
  start-page: 1160
  year: 2011
  ident: B79
  article-title: Brain cannabinoid CB2 receptors modulate cocaine's actions in mice
  publication-title: Nat Neurosci.
  doi: 10.1038/nn.2874
  contributor:
    fullname: Xi
– volume: 24
  start-page: 335
  year: 2016
  ident: B76
  article-title: Neurophysiology of substantia Nigra dopamine neurons: Modulation by GABA and glutamate
  publication-title: Handb Behav Neurosci.
  doi: 10.1016/B978-0-12-802206-1.00017-9
  contributor:
    fullname: Paladini
– volume: 384
  start-page: 83
  year: 1996
  ident: B21
  article-title: Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
  publication-title: Nature.
  doi: 10.1038/384083a0
  contributor:
    fullname: Cravatt
– volume: 167
  start-page: 107740
  year: 2020
  ident: B109
  article-title: Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-HT1A and TRPV1 receptor mechanisms
  publication-title: Neuropharmacology.
  doi: 10.1016/j.neuropharm.2019.107740
  contributor:
    fullname: Galaj
– volume: 28
  start-page: 39
  year: 2007
  ident: B140
  article-title: Cannabinoid CB2 receptor: a new target for controlling neural cell survival?
  publication-title: Trends Pharmacol Sci.
  doi: 10.1016/j.tips.2006.11.001
  contributor:
    fullname: Fernández-Ruiz
– volume: 23
  start-page: 187
  year: 2018
  ident: B14
  article-title: Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate
  publication-title: CNS Spectr.
  doi: 10.1017/S1092852918001013
  contributor:
    fullname: Stahl
– volume: 64
  start-page: 200
  year: 2016
  ident: B152
  article-title: Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson's disease
  publication-title: Prog Neuropsychopharmacol Biol Psychiatry.
  doi: 10.1016/j.pnpbp.2015.03.017
  contributor:
    fullname: Gómez-Gálvez
– volume: 22
  start-page: 374
  year: 2019
  ident: B119
  article-title: Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning
  publication-title: Nat Neurosci.
  doi: 10.1038/s41593-018-0334-7
  contributor:
    fullname: Sellgren
SSID ssj0000399365
Score 2.3840296
SecondaryResourceType review_article
Snippet Schizophrenia is a complex disorder that involves several neurotransmitters such as dopamine, glutamate, and GABA. More recently, the endocannabinoid system...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 587154
SubjectTerms cannabinoids
dopamine
endocannabinoid system
microglia
Psychiatry
psychosis
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LSwMxEA7iyYsovtYXETwJa7NJNmnwIG2xFEEvVugtJJsEvWxLHwf_vZNsW1oRvHjc3ewmfDM78w0ZviB0G4QrbCV9XviC5txVIbelJ7kBB3COOyuSXNPLqxi88-dROdo46iv2hDXywA1wLRIscG7PZAiES-KVBMIuGRAX3hbw7RR9Cd0oplIMjnlXlM02JlRhqhUms6_YO0nJfQlFQsm3ElHS6_-NZP7sldxIPv0DtL9kjbjTrPYQ7fj6CD10ph73uhQD9fOTeGoONhiCFh6m7m4MdBS_bfbU4eGqq_zxGA37T8PeIF-ehZBXXJTzXATVZpaEghIpDCtoEFFKTZVOFi5J6hjLCgdIBSNs5ZhqOyMr6TxcBsFO0G49rv0Zwo7CfweswxLluLKhbQy8JLiCiaQSVYbuVrjoSaN4oaFSiCDqBKKOIOoGxAx1I3LrgVGsOt0AE-qlCfVfJszQzQp3Dc4ddyxM7ceLmaYwXEGOJSpDp40d1lMxxqiCWjpDcstCW2vZflJ_fiQBbSkkY4qd_8fiL9BexCOlM3KJdufThb8CnjK318klvwF9KORu
  priority: 102
  providerName: Directory of Open Access Journals
Title Are CB2 Receptors a New Target for Schizophrenia Treatment?
URI https://www.ncbi.nlm.nih.gov/pubmed/33329132
https://search.proquest.com/docview/2470903609
https://pubmed.ncbi.nlm.nih.gov/PMC7673393
https://doaj.org/article/0fb626e37ff0470e97259731394864dc
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3PS-wwEB7Ukxd54q_6nhLBk9DdNGmTDR5EF0UERXAFbyFpEp_w7C7revC_d5JuZVc8vWPbhIRvpplvyJcJwHEQrrC19HnhC5aXrg65rTzNDTqAc6WzIpVrur0T14_lzVP1tAJVdxYmifZr-9Jr_r32mpe_SVs5ea37nU6sf387lEJyrnh_FVYx_C6k6Gn5jSFXVO0OJiZgqh8mbx9RNslor8L8oIp38XDOmSo4WwpHqWr_T1Tzu2JyIQRd_YKNOXck5-0cN2HFN1twej71ZHjBCBJAP4l35xBDcOkio6TxJkhKycOiso6MOm352TaMri5Hw-t8fiNCXpeimuUiqAG3NBSMSmF4wYKIBdVU5WThUmEdY3nhmPDBCFs7rgbOyFo6j49B8B1Ya8aN3wPiGP59yD0sVa5UNgyMwU6iVDiQVKLO4KTDRU_auhca84WIp0546oinbvHM4CIi99UwlqxOL8bTZz03nKbBYvLkuQyBlpJ6JTHzkhwZaDkQ6CQZHHW4a3TxuG9hGj9-f9MMmyuMtFRlsNva4Wuozo4ZyCULLc1l-Qt6VSqjPfei_f_u-RvWIwgpktE_sDabvvsDpCgze5hS-8PkmJ-rZ-cp
link.rule.ids 230,314,727,780,784,864,885,2102,27924,27925,53791,53793
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwEB2VcoALAvGV8mUkTkjZdezYXosDaletFuhWSASpN8uObajUZlfb7YF_z9jZVLuIU49JbNl6M_G8kZ_HAB-i9JVrVSirULGy9m0snQi0tOgA3tfeyVyuaX4mZz_rr-fifA_EcBYmi_ZbdzHqLq9G3cXvrK1cXrXjQSc2_j6fKqk413x8D-4LrnS1laTnBTgFXSn6PUxMwfQ4Lq__JOEkoyOBGYJIt_FwzpmuONsJSLlu___I5r-aya0gdPIYHm3YIznsZ_kE9kL3FD4drgKZHjGCFDAs0-05xBJcvEiTVd4EaSn5sa2tI82gLv_8DJqT42Y6Kzd3IpRtLcW6lFFPuKOxYlRJyysWZSqppoVXlc-ldazjlWcyRCtd67meeKta5QM-Rsmfw3636MJLIJ7h_4fsw1Hta-3ixFrsJGuNAykt2wI-DriYZV_5wmDGkPA0GU-T8DQ9ngUcJeRuG6ai1fnFYvXLbExnaHSYPgWuYqS1okErzL0URw5aTyS6SQHvB9wNOnnaubBdWNxcG4bNNcZaqgt40dvhdqjBjgWoHQvtzGX3C_pVLqS98aODO_d8Bw9mzfzUnH45-_YKHiZAclyjr2F_vboJb5CwrN3b7J5_AYsj6Yk
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1RaxQxEB60gvhSKlZdWzVCnwp7m012kwt9kPb0qNqWgif0LSSbRAt2b7leH_rvnWRvy5345OPuJiR8M5v5hnzMABwE4UrbSJ-XvmR55ZqQ29rT3KADOFc5K1K5pvMLcfqj-npVX621-kqi_cZej9rfN6P2-lfSVnY3TTHoxIrL84kUknPFi86F4jE8qTk62Vqing7hGHhF3d9jYhqmitDd3kfxJKOjGrOEOnbk4ZwzVXK2EZRS7f5_Ec6_dZNrgWi6A9srBkmO-50-h0e-fQFHxwtPJieMIA30XeygQwzBA4zMktKbIDUl39f1dWQ2KMw_7sJs-nk2Oc1XfRHyphL1MhdBjbmloWRUCsNLFkQsq6ZqJ0uXyusYy0vHhA9G2MZxNXZGNtJ5fAyCv4Stdt7610Acw38QGYilylXKhrExOElUCheSSjQZHA646K6vfqExa4h46oSnjnjqHs8MTiJyDwNj4er0Yr74qVfm0zRYTKE8lyHQSlKvJOZfkiMPrcYCXSWDDwPuGh093l6Y1s_vbjXD4QrjLVUZvOrt8LDUYMcM5IaFNvay-QV9KxXTXvnSm_-e-R6eXn6a6rMvF9_24FnEI4U2ug9by8Wdf4ucZWnfJe_8A_MA6pw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Are+CB2+Receptors+a+New+Target+for+Schizophrenia+Treatment%3F&rft.jtitle=Frontiers+in+psychiatry&rft.au=Cortez%2C+Isadora+L&rft.au=Rodrigues+da+Silva%2C+Naielly&rft.au=Guimar%C3%A3es%2C+Francisco+S&rft.au=Gomes%2C+Felipe+V&rft.date=2020-10-30&rft.issn=1664-0640&rft.eissn=1664-0640&rft.volume=11&rft.spage=587154&rft_id=info:doi/10.3389%2Ffpsyt.2020.587154&rft_id=info%3Apmid%2F33329132&rft.externalDocID=33329132
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-0640&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-0640&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-0640&client=summon